Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
Antimicrobial Resistance (AMR) poses a significant threat to global healthcare systems and patient safety
Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic
The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
Authorisation will help protect adults 60 years of age and older in 30 European countries* from RSV disease for the first time
European approval is based on robust Phase III data showing Cosentyx provided rapid symptom relief from as early as Week 4, with response rates continuing to improve up to 1 year1,3-5
Subscribe To Our Newsletter & Stay Updated
